▁Bre 8.03125
ast 1.9609375
▁cancer 1.6357421875
▁is 1.193359375
▁a 1.736328125
▁complex 3.8046875
▁disease 0.376953125
▁influenced 5.43359375
▁by 0.0206298828125
▁a 1.7470703125
▁mult 2.123046875
itude 0.002452850341796875
▁of 0.003143310546875
▁critical 9.9375
▁factors 0.607421875
, 1.169921875
▁including 0.63232421875
▁her 4.515625
ed 0.270263671875
ity 0.0002760887145996094
, 0.28759765625
▁dise 11.125
ases 0.042236328125
▁of 2.0703125
▁the 0.302734375
▁m 5.89453125
amm 0.038116455078125
ary 0.003398895263671875
▁g 0.147705078125
lands 0.8984375
, 0.26806640625
▁and 1.609375
▁h 2.80859375
orm 0.0022907257080078125
onal 0.7177734375
▁im 2.685546875
bal 0.000293731689453125
ances 0.392333984375
. 0.1837158203125
▁Under 5.578125
standing 0.1302490234375
▁these 1.404296875
▁factors 0.55029296875
▁is 1.1689453125
▁p 5.67578125
iv 0.004669189453125
otal 8.749961853027344e-05
▁in 1.2900390625
▁compreh 5.9921875
ending 0.274169921875
▁the 0.66064453125
▁development 2.91015625
▁of 0.3125
▁breast 0.60888671875
▁cancer 0.02587890625
▁and 1.0478515625
▁implementing 4.546875
▁effective 1.2587890625
▁prevent 1.359375
ion 0.6435546875
▁strateg 1.2734375
ies 4.589557647705078e-05
. 0.1512451171875
<0x0A> 0.93212890625
H 3.529296875
ered 0.62451171875
ity 0.0015935897827148438
▁plays 2.626953125
▁a 0.272705078125
▁significant 1.1640625
▁role 0.0208587646484375
▁in 0.0380859375
▁breast 1.396484375
▁cancer 0.0084075927734375
▁sus 3.923828125
cept 5.257129669189453e-05
ibility 0.00072479248046875
. 0.5634765625
▁Ind 4.15234375
ividual 0.0028476715087890625
s 0.0171661376953125
▁with 0.49267578125
▁a 0.3564453125
▁family 0.42822265625
▁history 0.01495361328125
▁of 0.055572509765625
▁the 1.7412109375
▁disease 0.052001953125
, 2.546875
▁especially 1.41015625
▁those 1.03125
▁carrying 4.3828125
▁specific 3.142578125
▁gen 0.63818359375
etic 0.353759765625
▁mut 0.26953125
ations 0.002471923828125
▁such 2.234375
▁as 0.00322723388671875
▁BR 0.11871337890625
CA 0.0025691986083984375
1 0.08563232421875
▁and 0.473388671875
▁BR 0.0182342529296875
CA 0.0006532669067382812
2 0.004302978515625
, 0.06658935546875
▁are 0.3896484375
▁at 0.256591796875
▁a 0.783203125
▁higher 0.47509765625
▁risk 0.0026149749755859375
. 2.322265625
▁These 2.853515625
▁mut 0.453369140625
ations 0.002559661865234375
▁imp 4.4375
air 0.058685302734375
▁the 0.677734375
▁body 1.4306640625
' 1.2373046875
s 8.034706115722656e-05
▁ability 0.180419921875
▁to 0.0003027915954589844
▁suppress 5.609375
▁tum 0.44091796875
or 0.187744140625
▁growth 0.499755859375
▁and 1.2724609375
▁repair 2.71484375
▁DNA 1.2255859375
. 3.451171875
▁Close 9.875
▁relatives 0.53076171875
▁of 0.3984375
▁affected 2.3359375
▁individuals 0.143798828125
▁should 3.376953125
▁under 0.962890625
go 0.0001245737075805664
▁gen 0.6669921875
etic 0.0004210472106933594
▁coun 2.904296875
sel 0.034210205078125
ing 0.0001608133316040039
▁and 0.70849609375
▁testing 0.75390625
▁to 0.18310546875
▁determine 0.66845703125
▁their 0.1376953125
▁own 2.78125
▁risk 0.1885986328125
▁and 2.095703125
▁make 2.861328125
▁informed 0.11688232421875
▁dec 0.20556640625
isions 8.344650268554688e-06
▁regarding 1.8740234375
▁prevent 0.77734375
ive 0.576171875
▁measures 0.1058349609375
, 3.5390625
▁such 0.229248046875
▁as 0.00023794174194335938
▁regular 0.6943359375
▁screen 0.6953125
ings 1.4296875
▁or 3.3359375
▁pro 1.3935546875
phy 0.00885009765625
la 1.8358230590820312e-05
ctic 0.0005340576171875
▁surg 0.79443359375
ery 0.003093719482421875
. 0.03173828125
<0x0A> 0.0770263671875
D 1.3232421875
ise 0.006378173828125
ases 0.0130462646484375
▁of 0.07574462890625
▁the 0.0031185150146484375
▁m 0.1610107421875
amm 0.00015926361083984375
ary 0.000568389892578125
▁g 0.0016374588012695312
lands 0.0267486572265625
, 0.2198486328125
▁such 0.41259765625
▁as 0.00013339519500732422
▁at 4.1171875
yp 0.021636962890625
ical 0.01377105712890625
▁hyper 0.2432861328125
pl 0.00017464160919189453
asia 0.0098419189453125
▁or 2.138671875
▁car 5.51171875
cin 9.322166442871094e-05
oma 0.0098114013671875
▁in 0.026641845703125
▁situ 0.002593994140625
, 0.143798828125
▁can 0.57763671875
▁increase 1.0556640625
▁the 0.210205078125
▁risk 0.04681396484375
▁of 0.016143798828125
▁breast 0.6982421875
▁cancer 0.0005269050598144531
. 0.1771240234375
▁These 1.07421875
▁conditions 0.291259765625
▁involve 2.048828125
▁ab 0.4326171875
normal 0.0007891654968261719
▁cell 0.5908203125
ular 2.916015625
▁growth 0.174560546875
▁or 3.650390625
▁pre 2.416015625
can 0.258544921875
cer 9.179115295410156e-05
ous 0.0005340576171875
▁changes 0.392822265625
▁in 0.443603515625
▁the 0.00693511962890625
▁breast 0.8173828125
▁t 0.198486328125
issue 0.00760650634765625
. 1.2216796875
▁Reg 2.59765625
ular 0.00019240379333496094
▁breast 1.576171875
▁exam 1.4248046875
in 0.102294921875
ations 1.7881393432617188e-05
▁and 0.27734375
▁m 0.1402587890625
amm 4.291534423828125e-06
og 0.3955078125
rams 5.364418029785156e-05
▁are 1.076171875
▁cru 1.2255859375
cial 2.2649765014648438e-06
▁in 0.638671875
▁detect 0.24365234375
ing 2.0265579223632812e-06
▁these 0.51220703125
▁dise 2.490234375
ases 1.621246337890625e-05
▁at 2.53515625
▁an 0.03985595703125
▁early 0.00136566162109375
▁stage 0.0037517547607421875
▁when 3.138671875
▁they 0.64208984375
▁are 0.326171875
▁highly 5.3828125
▁treat 0.0882568359375
able 1.1920928955078125e-06
. 0.037689208984375
▁Prom 7.4765625
pt 0.326904296875
▁diagn 2.3046875
osis 0.00092315673828125
▁and 0.03424072265625
▁appropriate 3.18359375
▁inter 2.765625
vent 0.266357421875
ions 0.0017118453979492188
▁can 0.440185546875
▁reduce 1.810546875
▁the 0.0135345458984375
▁lik 2.80078125
elihood 1.0609626770019531e-05
▁of 0.0031890869140625
▁m 2.8828125
align 0.07281494140625
ant 0.1668701171875
▁transformation 0.51025390625
▁and 0.712890625
▁the 3.103515625
▁subsequent 3.4609375
▁development 0.23291015625
▁of 0.00021576881408691406
▁invas 3.607421875
ive 4.76837158203125e-06
▁breast 0.357666015625
▁cancer 0.002902984619140625
. 0.004425048828125
<0x0A> 0.0208587646484375
H 0.30712890625
orm 0.00031256675720214844
onal 0.04656982421875
▁factors 4.5859375
▁also 1.314453125
▁contribute 3.078125
▁significantly 4.21875
▁to 0.006587982177734375
▁the 0.77197265625
▁development 0.69091796875
▁of 0.04144287109375
▁breast 0.01331329345703125
▁cancer 0.0003848075866699219
. 0.0411376953125
▁Est 0.853515625
ro 0.012298583984375
gen 2.3484230041503906e-05
▁and 0.5947265625
▁pro 0.007549285888671875
g 0.0068511962890625
ester 4.887580871582031e-06
one 0.0001609325408935547
▁re 4.0625
cept 0.062103271484375
ors 0.0018310546875
, 2.318359375
▁prote 4.9609375
ins 1.4424324035644531e-05
▁found 1.2939453125
▁on 0.7041015625
▁breast 3.244140625
▁cells 1.23046875
, 0.0916748046875
▁interact 4.83203125
▁with 0.0042724609375
▁these 0.83642578125
▁h 0.0278167724609375
orm -0.0
ones 0.0005540847778320312
▁and 2.310546875
▁promote 2.91015625
▁cell 1.3505859375
▁growth 1.0078125
. 0.51171875
▁A 4.515625
▁prolong 4.71875
ed 9.310245513916016e-05
▁expos 0.436767578125
ure 8.344650268554688e-06
▁to 0.0489501953125
▁elev 3.212890625
ated 2.0503997802734375e-05
▁h 2.76171875
orm 1.0728836059570312e-06
onal 1.984375
▁levels 0.006542205810546875
, 1.1328125
▁either 2.591796875
▁due 1.369140625
▁to 0.00010061264038085938
▁early 4.51171875
▁men 0.2415771484375
stru 2.841796875
ation 0.04443359375
, 0.341796875
▁late 0.41748046875
▁men 0.0916748046875
op 0.0009393692016601562
ause 0.0007500648498535156
, 0.0205078125
▁or 0.2122802734375
▁the 1.541015625
▁use 0.08551025390625
▁of 0.00012600421905517578
▁h 0.54248046875
orm 5.960464477539062e-07
one 0.1484375
▁replacement 0.07232666015625
▁ther 0.0007476806640625
apy 0.034698486328125
, 0.25634765625
▁increases 1.4599609375
▁the 0.04449462890625
▁risk 0.0238494873046875
▁of 0.0292816162109375
▁breast 0.2430419921875
▁cancer 0.0023670196533203125
. 0.06353759765625
▁Under 4.19140625
standing 0.0164031982421875
▁the 0.8203125
▁h 3.548828125
orm 1.3947486877441406e-05
onal 0.04876708984375
▁profile 2.5234375
▁of 0.51806640625
▁an 0.75634765625
▁individual 0.01038360595703125
▁can 2.275390625
▁aid 2.328125
▁in 0.008636474609375
▁de 5.51953125
vis 0.007457733154296875
ing 4.76837158203125e-07
▁personal 1.4287109375
ized 0.0012388229370117188
▁prevent 0.276123046875
ion 0.323974609375
▁strateg 0.171142578125
ies 1.430511474609375e-06
, 0.68896484375
▁such 0.18115234375
▁as 4.1961669921875e-05
▁h 1.873046875
orm 3.135204315185547e-05
one 0.63330078125
- 0.982421875
block 0.63671875
ing 0.00289154052734375
▁medic 0.7890625
ations 0.1170654296875
▁or 0.342529296875
▁l 0.35009765625
ifest 6.318092346191406e-06
yle 7.140636444091797e-05
▁modifications 0.32373046875
. 0.7548828125
<0x0A> 0.0218963623046875
Det 7.08984375
ect 0.2000732421875
ing 0.0130462646484375
▁early 2.650390625
▁met 8.9453125
ast 0.8193359375
asis 1.0478515625
▁is 1.7216796875
▁cru 1.0107421875
cial 0.00048351287841796875
▁in 0.42626953125
▁determ 4.4765625
ining 0.00016999244689941406
▁the 0.395751953125
▁pro 1.798828125
gn 0.0281219482421875
osis 0.0026073455810546875
▁and 0.83203125
▁treatment 0.87548828125
▁of 1.271484375
▁breast 0.235107421875
▁cancer 0.001430511474609375
. 0.130859375
▁Met 2.66796875
ast 0.0104522705078125
asis 0.12347412109375
▁occurs 1.2666015625
▁when 0.01027679443359375
▁cancer 0.1690673828125
▁cells 0.1729736328125
▁spread 0.180908203125
▁from 1.4697265625
▁the 0.22900390625
▁primary 0.91357421875
▁tum 0.99560546875
or 0.002719879150390625
▁to 0.82275390625
▁other 0.1651611328125
▁parts 0.51025390625
▁of 0.00020205974578857422
▁the 9.369850158691406e-05
▁body 0.00012087821960449219
, 0.18115234375
▁leading 3.2578125
▁to 0.00015401840209960938
▁a 1.171875
▁more 0.60791015625
▁advanced 0.71728515625
▁stage 0.92138671875
▁of 0.060455322265625
▁the 0.11932373046875
▁disease 0.0019741058349609375
. 0.262939453125
▁Reg 4.078125
ular 0.0019893646240234375
▁screen 0.5947265625
ings 0.50439453125
, 0.5302734375
▁such 0.224853515625
▁as 5.3763389587402344e-05
▁m 0.1241455078125
amm 9.655952453613281e-06
og 0.0965576171875
rams 1.5974044799804688e-05
, 0.8876953125
▁help 4.63671875
▁identify 1.759765625
▁breast 3.166015625
▁cancer 0.031829833984375
▁at 0.40185546875
▁an 0.12017822265625
▁early 0.03741455078125
▁stage 0.0194854736328125
▁before 2.033203125
▁it 0.2109375
▁has 0.32177734375
▁had 2.091796875
▁the 0.919921875
▁chance 1.2646484375
▁to 0.0002455711364746094
▁spread 0.24267578125
. 0.174560546875
▁Additionally 3.435546875
, 0.0001207590103149414
▁special 5.7578125
ized 0.111572265625
▁imag 0.9794921875
ing 0.0002562999725341797
▁techniques 0.280029296875
, 0.2083740234375
▁such 0.10003662109375
▁as 0.0001538991928100586
▁M 1.494140625
RI 0.0006504058837890625
▁or 1.81640625
▁P 0.462158203125
ET 0.00030159950256347656
▁sc 0.12548828125
ans 0.006649017333984375
, 0.004611968994140625
▁can 0.254150390625
▁help 2.09765625
▁detect 0.276123046875
▁met 1.07421875
ast 7.891654968261719e-05
atic 2.509765625
▁les 1.76171875
ions 0.00018155574798583984
▁in 0.452392578125
▁distant 2.53515625
▁org 0.059051513671875
ans 1.0728836059570312e-06
. 0.541015625
▁Tim 3.828125
ely 0.00010883808135986328
▁detection 1.236328125
▁of 0.912109375
▁met 0.08746337890625
ast 5.161762237548828e-05
asis 0.228515625
▁allows 1.515625
▁for 0.05322265625
▁the 2.76171875
▁implementation 0.70263671875
▁of 5.5670738220214844e-05
▁target 1.8916015625
ed 0.00011074542999267578
▁ther 0.623046875
ap 0.035247802734375
ies 2.6226043701171875e-06
▁and 1.2822265625
▁impro 1.943359375
ves 0.0009860992431640625
▁patient 2.921875
▁out 0.173828125
comes 0.0002560615539550781
. 0.022674560546875
<0x0A> 0.08551025390625
Det 5.54296875
erm 1.7861328125
ining 0.04937744140625
▁the 0.1982421875
▁ag 3.701171875
gress 0.002994537353515625
iveness 0.0156097412109375
▁of 0.053497314453125
▁breast 0.405517578125
▁cancer 0.004547119140625
▁is 0.18896484375
▁essential 1.6845703125
▁for 1.927734375
▁determ 3.828125
ining 7.18832015991211e-05
▁the 0.221923828125
▁most 1.7177734375
▁suitable 2.421875
▁treatment 0.09930419921875
▁plan 1.1943359375
. 0.11175537109375
▁Path 5.04296875
olog 0.806640625
ists 0.282958984375
▁analyze 2.240234375
▁tum 2.431640625
or 0.106201171875
▁samples 0.7685546875
▁to 0.615234375
▁identify 3.07421875
▁specific 1.435546875
▁cell 4.11328125
ular 0.290771484375
▁characteristics 1.1201171875
, 0.79931640625
▁such 0.228515625
▁as 2.2172927856445312e-05
▁the 0.465087890625
▁tum 6.12109375
or 0.0023899078369140625
▁grade 0.9453125
▁or 1.5380859375
▁the 0.8876953125
▁presence 0.5341796875
▁of 0.0024261474609375
▁specific 1.361328125
▁bi 2.15234375
om 0.00811004638671875
ark 0.0009002685546875
ers 0.0009741783142089844
▁like 5.58984375
▁human 3.74609375
▁e 0.00597381591796875
pid 0.0009398460388183594
erm 0.0008692741394042969
al 0.00033664703369140625
▁growth 0.003261566162109375
▁factor 0.0029811859130859375
▁re 0.07049560546875
ceptor 0.06488037109375
▁ 0.1441650390625
2 0.00010848045349121094
▁( 0.058990478515625
HER 0.002727508544921875
2 0.052093505859375
). 0.42529296875
▁These 1.1796875
▁factors 1.45703125
▁allow 5.94921875
▁health 2.923828125
care 0.02398681640625
▁profession 0.92138671875
als 1.3113021850585938e-06
▁to 0.0011539459228515625
▁recommend 4.03125
▁appropriate 1.962890625
▁treatment 0.91650390625
▁options 0.284423828125
, 0.196533203125
▁including 1.1337890625
▁surg 0.1383056640625
ery 0.094482421875
, 0.0048370361328125
▁chem 0.421875
other 0.00016546249389648438
apy 2.0742416381835938e-05
, 0.0031757354736328125
▁radiation 1.884765625
▁ther 0.1923828125
apy 4.100799560546875e-05
, 0.0074462890625
▁or 0.342041015625
▁target 0.46923828125
ed 0.00028824806213378906
▁ther 0.018798828125
apy 0.98388671875
. 0.2479248046875
<0x0A> 1.1044921875
In 2.46484375
▁conclusion 0.4033203125
, 0.00021147727966308594
▁breast 1.3349609375
▁cancer 0.0007534027099609375
▁development 6.81640625
▁is 0.281005859375
▁influenced 1.7470703125
▁by 0.0003185272216796875
▁critical 7.1796875
▁factors 0.054473876953125
▁such 1.2216796875
▁as 0.0002677440643310547
▁her 0.11114501953125
ed 0.00881195068359375
ity 3.337860107421875e-06
, 0.0019683837890625
▁dise 0.56640625
ases 0.0004398822784423828
▁of 0.002285003662109375
▁the 0.005527496337890625
▁m 0.004486083984375
amm 0.00014328956604003906
ary 0.00016427040100097656
▁g 0.0009479522705078125
lands 0.00890350341796875
, 0.00293731689453125
▁and 0.787109375
▁h 0.00447845458984375
orm 8.344650268554688e-07
onal 0.0109100341796875
▁im 0.06915283203125
bal 2.2411346435546875e-05
ances 0.00484466552734375
. 0.068359375
▁Det 3.625
ect 0.020965576171875
ing 0.0001049041748046875
▁early 0.224609375
▁met 0.1461181640625
ast 3.147125244140625e-05
asis 0.01398468017578125
▁and 0.50732421875
▁understanding 2.298828125
▁the 0.109130859375
▁ag 0.08294677734375
gress 0.0003600120544433594
iveness 0.0045928955078125
▁of 0.00815582275390625
▁the 0.21875
▁cancer 2.28125
▁type 9.0546875
▁play 4.11328125
▁a 0.39794921875
▁substantial 8.2578125
▁role 0.0024738311767578125
▁in 0.0008053779602050781
▁tail 4.68359375
oring 0.0260009765625
▁treatment 2.13671875
▁approaches 3.921875
▁and 0.7744140625
▁impro 0.2174072265625
ving 5.161762237548828e-05
▁patient 0.089599609375
▁out 0.0141448974609375
comes 1.4185905456542969e-05
. 0.0030765533447265625
▁Through 5.66796875
▁increased 6.14453125
▁aw 0.053466796875
aren 5.960464477539062e-07
ess 1.6689300537109375e-06
, 0.85302734375
▁gen 5.3125
etic 0.0002675056457519531
▁testing 0.7001953125
, 0.052001953125
▁regular 0.79736328125
▁screen 0.1551513671875
ings 0.1307373046875
, 0.01390838623046875
▁and 0.1185302734375
▁improved 5.6015625
▁di 1.0927734375
agnostic 0.10638427734375
▁methods 2.251953125
, 0.002620697021484375
▁we 0.55029296875
▁can 0.0083160400390625
▁enh 3.5234375
ance 1.5020370483398438e-05
▁early 3.220703125
▁detection 0.1781005859375
, 1.5810546875
▁inter 7.171875
vention 0.211181640625
, 0.0172576904296875
▁and 0.0028171539306640625
▁prevent 0.97607421875
ion 0.0250701904296875
▁strateg 2.3359375
ies 5.7220458984375e-06
, 1.33984375
▁ultimately 0.80908203125
▁reducing 0.72900390625
▁the 0.058197021484375
▁impact 3.017578125
▁of 0.0208587646484375
▁breast 0.4228515625
▁cancer 0.0001837015151977539
▁on 0.19873046875
▁individuals 0.440185546875
▁and 0.09552001953125
▁society 0.8349609375
▁as 1.462890625
▁a 0.0008525848388671875
▁whole 3.1948089599609375e-05
. 0.00878143310546875
